Transgenic models of inflammatory disease
US6437216B1 · kind B1 · utility
6Cited by
1References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 12, 2001 |
| Grant date | Aug 20, 2002 |
| Priority date | — |
| Expiry date | Mar 12, 2021 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2800/30
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present provides a mammal in which the expression of one or more interleukin genes has been suppressed. More specifically, the invention concerns the inactivating deletion of the interleukin-1 receptor antagonist gene to produce a knock-out non-human mammal with decreased or completely suppressed expression of the endogenous gene. The invention provides methods for preparing such knock-out mammals and methods of using the knock-out mammals to evaluate the effectiveness of therapeutic agents and regimens to treat diseases or disorders associated with perturbations in the interleukin pathways.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.